SAFETY, EFFICACY AND LESSONS FROM CONTINUOUS-INFUSION WITH RFVIIA

Continuous infusion with coagulation factor concentrates has only been widely adapted during the last decade and with recombinant activated factor VII (rFVIIa) only during the last 2 years. Still the accumulate d number of days on continuous infusion with this product amounts by n ow to more than one year, 35 patients and 26 surgical procedures. The experience is reviewed here and compared with data from the convention al bolus dose regimen.